

Seroprevalence Of Hepatitis B Surface Antigenaemia In Children In A Tertiary Health Institution In The Niger Delta Of Nigeria

¹Edward A. D. Alikor, ²Osaro N. Erhabor

Department Of Pediatrics¹, Department Of Hematology² University Of Port Harcourt Teaching Hospital Port Harcourt Nigeria

Abstract

Background: There is paucity of data on the seroprevalence of HBV infection in children living in urban areas of the Niger Delta of Nigeria. The aim of this study is to determine the seroprevalence of hepatitis B surface antigenaemia among children presenting to the University of Port Harcourt Teaching Hospital (UPTH), to determine the trend in the seroprevalence of HBsAg over a five-year period and to correlate serological findings to clinical features.

Methods: A retrospective study of Serum samples from 251 children in UPTH aged ≥ 16 years which were tested for Hepatitis B surface antigen using Clinotech HBsAg kits and confirmed using the Trinity Biotec enzyme linked immunosorbent assay based HBsAg kits. Medical records of the children were also obtained.

Results: The overall prevalence of HBsAg among children tested was 12.4%. HBsAg prevalence was highest in the 11-15 years age group (24.5%) and the lowest in the 6 - 10 years age group (11.0%). There was a statistically significant difference in the prevalence of HBV positivity based on age groups ($\chi^2 = 8.47, p = 0.014$). Prevalence rate was relatively higher among males (13.7%) compared to females (10.7%). There is a statistically significant trend in the decline of HBsAg prevalence 1999 to 2004 (χ^2 for trend = 11.38, $p = 0.001$). The predominant symptoms among children positive for HBsAg were hepatosplenomegaly (75%) and jaundice (64.5%).

Conclusion: This study indicates a high prevalence of HBsAg among children presenting to a tertiary health facility in Port Harcourt.

Key Words: Seroprevalence, HBsAg, Paediatrics, Niger Delta, Nigeria.

Paper accepted for publication 22nd November 2006

INTRODUCTION

Hepatitis B virus (HBV) infection is a global public health problem and a significant cause of morbidity and mortality¹. Globally, more than 2 billion people have serological evidence of HBV infection and over 350 million are chronic carriers of the virus.^{2,3}

The prevalence of HBV infection varies greatly depending on the geographical region. In high endemicity regions particularly in developing countries, the prevalence is higher than 10% while in areas of intermediate endemicity the prevalence ranges between 2-10%.⁴ In Southern and Eastern Asia, up to 50% of chronic HBV infection results from perinatal transmission from mother to child during or soon after birth.⁵ In some countries the use of a combined passive/active immunization strategy to prevent perinatal infection has dramatically reduced the incidence of chronic HBV infection, the incidence of primary hepatocellular carcinoma (PHCC) and cases of acute fulminant hepatitis B among children.^{6,7} In Nigeria, studies in adult population obtained prevalence of 7-11% in blood donors and HIV-infected parients^{8, 9} and 38% in patients with liver diseases.¹⁰ In some African studies high prevalence rates have been reported.¹¹⁻¹³

There is paucity of data on the seroprevalence of HBV infection in children living in urban areas of the Niger Delta of Nigeria. The objective of this study is to determine the seroprevalence of HBV among children presenting to the University of Port Harcourt Teaching Hospital in the Niger Delta of Nigeria, and to examine the trend in the seroprevalence of HBsAg over a five-year period and to determine the association between HBsAg seroprevalence and the presenting symptoms and signs.

MATERIALS AND METHOD

The subjects for this study were 251 retrospectively studied children less than 16 years old seen at the children department of the University of Port Harcourt Teaching Hospital, a five hundred-bed tertiary health facility in the cosmopolitan city of Port Harcourt between 1st January 1999 and 31st December 2004. Subjects were in- and out-patients seen in the Hospital within the stated period in whom the clinicians have sufficient reason to suspect hepatitis B and then request for screening. Demographic information about each child as well as history of HBV vaccination, history of blood transfusion and information on the clinical features

presented by the subjects including presence of hepatosplenomegaly, jaundice, sickle cell disease, nephropathy, anaemia and malaria where extracted from the patients medical records. Informed consent were obtained from the parent or caregiver.

Venous blood samples were collected from all study subjects. Serum samples were separated and stored at -20oC prior to serological testing. All samples were screened using the commercially available Clinotech HBsAg kit (Clinotech Diagnostics, Canada), a one step hepatitis B surface antigen rapid chromatographic immunoassay test for the qualitative detection of hepatitis B surface antigen in serum. Initially reactive samples were confirmed using a second-generation Trinity Biotec enzyme-linked immunosorbent assay (Trinity Biotec, Ireland).

RESULTS

A total of 251 children aged 0 -16 years (mean age 5.11 + 4.28 years) made up of 139 males and 112 females (M: F=1.2:1.0) constituted the subjects for this study. Thirty one children tested positive for HBsAg, giving an overall prevalence of Hepatitis B surface antigenaemia (HBsAg) of 12.4%. The age distribution of HBsAg positivity is shown in figure 1. HBsAg prevalence was highest in the 11-15 years age group (24.5%) and the lowest in the 6 - 10 years age group (11.0%). There was a statistically significant difference in the prevalence of HBV positivity based on the various age groups (+2 = 8.47, p = 0.014). Nineteen out of the 139 (13.7%) males in the study group tested positive for HBsAg compared to 12 out of the 112 females (10.7%). This difference is not statistically significant (+2 = 0.26, p = 0.607). The prevalence of HBsAg was higher among children that presented with hepatosplenomegaly, jaundice, nephropathy and sickle cell disease (Table 1). No case of HBV positivity was found among patients who presented with neonatal jaundice, human immunodeficiency virus (HIV) infection, pulmonary tuberculosis, persistent fever and septicemia. No patient had history of previous HBV vaccination. The trend of a decrease in HBsAg prevalence from 1999 to 2004 was statistically significant (+2 for trend = 11.83, p= 0.001). This is shown in figure 2.

Fig 1: Age distribution of HBsAg among the study group




Fig 2: Trend in Prevalence of HBsAg in the study group




Table 1: Prevalence of HBsAg positivity among the study group based on presenting Clinical Features/Problems.

Clinical features/Problems	Number Screened	Number HBsAg positive	% Positive
Hepatosplenomegaly	4	3	75.0
Jaundice(excluding neonatal)	62	20	32.3
Sickle Cell Disease	4	1	25.0
Nephropathy	23	4	17.4
Anemia	20	1	5.0
Malaria	59	2	3.4
Human immunodeficiency virus/ AIDS	26	0	0.0
Neonatal jaundice	24	0	0.0
Tuberculosis	4	0	0.0
Septicaemia	7	0	0.0
Others	18	0	0.0
TOTAL	251	31	12.4